Cytovance Biologics Expands GMP Warehouse and Manufacturing Operations - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Cytovance Biologics Expands GMP Warehouse and Manufacturing Operations



Cytovance Biologics, a full-service contract manufacturer of mammalian and microbial biologics, continues to work on the expansion of a manufacturing operations and GMP warehousing facility. The multi-million dollar capital investment project is expected to be completed by June 2014.
 
Cytovance selected a construction site two miles north of its current campus in Oklahoma.  The new facility, located at 3500 N. Santa Fe, will house 20,000 ft2 of climate controlled and monitored GMP warehouse space and 10,000 ft2 of space for existing and future manufacturing operations. Initially, this cleanroom space will be used for weighing and dispensing activities.
 
“Our new GMP warehouse will support incoming and outgoing supply-chain activities and provide full segregation between incoming, quarantine, and released materials,” explained Don Wuchterl, senior vice-president of manufacturing operations in a press release.

Source: Cytovance Biologics

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
35%
Breakthrough designations
12%
Protecting the supply chain
35%
Expedited reviews of drug submissions
12%
More stakeholder involvement
6%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges

Click here